SAN FRANCISCO — The phase 1b study of KSI-301, a novel anti-VEGF antibody polymer, improved best corrected visual acuity, showed strong efficacy and safety for patients with either wet age-related macular degeneration, diabetic macular edema/diabetic retinopathy or retinal vein occlusion, according to a speaker here.
“KSI-301, an anti-VEGF ABC, has already achieved important milestones, including excellent safety, no cases of intraocular inflammation across 300 plus doses, and strong efficacy across the three major phenotypically variable retinal diseases,” Charles C. Wykoff,
Uncategorized